Antibody Treatment in Multiple Myeloma

Abstract: Antibody therapy, which has become a critical option in the treatment of multiple myeloma (MM), includes monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Anti-CD38 and […]

Current Antibody-Based Therapies for the Treatment of Multiple Myeloma

  Abstract: Despite continued and considerable progress following the introduction of proteasome inhibitors and immunomodulatory agents, multiple myeloma (MM) remains an incurable disease, and new therapeutic […]

Advances in CAR T-Cell Therapy for the Treatment of Multiple Myeloma

  H&O  What is the rationale for the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? NS  Multiple myeloma cells express B-cell maturation […]

HIV Protease Inhibitors for the Treatment of Multiple Myeloma 

  Abstract: Outcomes in multiple myeloma (MM) patients have improved in recent years owing to the introduction of new drugs. Among them, proteasome inhibitors and immunomodulatory […]

Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma Is Ready for Prime Time 

  Abstract: The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose […]

The Role of JAK Inhibitors in Multiple Myeloma

  Abstract  Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with […]

Insights Into the Management of Older Patients With Multiple Myeloma

  H&O  What is the age distribution among patients with multiple myeloma? KA  Studies have shown that the median age of patients with multiple myeloma is […]

CAR T-Cell Therapy Against B-Cell Maturation Antigen in Multiple Myeloma

  H&O  Could you please describe B-cell maturation antigen? AC  B-cell maturation antigen (BCMA) is a cell-surface receptor that is expressed primarily by plasma cells, including […]

The Evolving Role of Transplantation in Multiple Myeloma: the Need for a Heterogeneous Approach to a Heterogeneous Disease

  Abstract: Autologous stem cell transplant (ASCT) is an established frontline standard of care for the younger, fitter patients with newly diagnosed multiple myeloma (NDMM) who […]

Emerging Options for Combination Therapy in Multiple Myeloma

  H&O  How has the diagnosis of multiple myeloma evolved? AR  Previously, the definition of active disease required the presence of myeloma cells, an M spike, […]

Monitoring Multiple Myeloma

  Abstract:  Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in bone marrow of terminally differentiated plasma cells. MM is a slowly growing, […]

Incorporating Monoclonal Antibodies Into the Management of Multiple Myeloma

  H&O  How do monoclonal antibodies work? TM  Monoclonal antibodies are immunoglobulins (Igs) that are generated and manufactured to target a specific antigen present on a […]

The Effect of Novel Therapies in High-Molecular-Risk Multiple Myeloma

  Abstract:  Multiple myeloma is a heterogeneous disease with a prognosis that varies with patient factors, disease burden, tumor biology, and treatments. Certain molecular abnormalities confer […]

When to Initiate Treatment in Smoldering Multiple Myeloma

  H&O  How is smoldering multiple myeloma defined? MM  Smoldering multiple myeloma is a plasma cell dis­order defined by the presence of a serum monoclonal component […]

The Role of Autologous Stem Cell Transplant in Patients With Multiple Myeloma

  H&O  What are the clinical characteristics of multiple myeloma? JM  Multiple myeloma has historically been defined by 4 clinical characteristics: elevated calcium, renal deficiency, anemia, […]

Use of Genetic Markers in Multiple Myeloma

  H&O  In what ways is multiple myeloma a genetically heterogeneous disease? RF  In an editorial written several years ago, I referred to this disease as […]

Myeloma Bone Disease: Pathogenesis and Treatment

  Abstract: Bone involvement manifesting as osteolytic bone disease (OBD) or osteopenia is one of the defining features of multiple myeloma (MM). Osteolytic lesions develop in […]

Monoclonal Antibodies in Multiple Myeloma: Data From the 2015 ASH Meeting

H&O What are the most important principles in the management of multiple myeloma? SL In the past few years, treatment options for myeloma have increased and […]